http://www.amgennews.com/index.php en pmannle@amgen.com Copyright 2009 2009-06-10T19:44:00+00:00 http://www.amgennews.com/index.php/2008NewsService/statement_in_response_to_ftc_report_on_biosimilars/ http://www.amgennews.com/index.php/2008NewsService/statement_in_response_to_ftc_report_on_biosimilars/#When:19:44:00Z THOUSAND OAKS, Calif.–June 10, 2009–As a biotechnology pioneer committed to developing first-in-class medicines that treat serious illnesses and unmet health needs, Amgen believes that an abbreviated biosimilar approval pathway must not discourage the development of groundbreaking new treatments for serious diseases.  Company Statements 2009-06-10T19:44:00+00:00 http://www.amgennews.com/index.php/2008NewsService/new_study_shows_nplater_significantly_reduces_splenectomy_rate_and_treatmen/ http://www.amgennews.com/index.php/2008NewsService/new_study_shows_nplater_significantly_reduces_splenectomy_rate_and_treatmen/#When:09:42:00Z BERLIN – June 7 – Amgen Inc. (Nasdaq: AMGN) today released the results of a new study comparing Nplate(R) (romiplostim) to the medical standard of care (SOC) in non-splenectomised adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic ITP is a serious autoimmune disorder characterised by low platelet counts in the blood (thrombocytopenia), which can lead to serious bleeding events. The study results show Nplate significantly reduced the incidences of splenectomy and treatment failures in non-splenectomised adult patients with chronic ITP when compared to medical SOC. The results were presented today as an oral presentation at the 14th congress of the European Hematology Association (EHA abstract #1672). Press Releases, Product News 2009-06-08T09:42:00+00:00 http://www.amgennews.com/index.php/2008NewsService/new_survey_highlights_growing_concern_about_risk_of_infection_in_cancer_pat/ http://www.amgennews.com/index.php/2008NewsService/new_survey_highlights_growing_concern_about_risk_of_infection_in_cancer_pat/#When:06:00:00Z Amgen, CDC Foundation and CDC Partner to Launch Three-Year Initiative to Improve Infection Control in Vulnerable Cancer Patient Population THOUSAND OAKS, Calif. – May 27, 2009 – Amgen (Nasdaq: AMGN) today announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy patients, as well as emerging antibiotic resistance. Nearly all oncologists surveyed (92 percent) believe it is important for cancer patients to prevent infections to achieve successful treatment outcomes. Antibiotic resistance is a growing concern among the majority of physicians surveyed, with 96 percent of ID specialists and 79 percent of oncologists reporting an increase in antibiotic-resistant infections in cancer patients over the past five years. Both groups of physicians report methicillin-resistant Staphylococcus aureus (MRSA) infections as the most commonly observed in chemotherapy patients.   Press Releases 2009-05-27T06:00:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_exercises_option_for_exclusive_license_to_cytokinetics_cardiac_contra/ http://www.amgennews.com/index.php/2008NewsService/amgen_exercises_option_for_exclusive_license_to_cytokinetics_cardiac_contra/#When:09:14:00Z Cytokinetics Receives Exercise Fee of $50 Million; Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/—Cytokinetics Incorporated (Nasdaq: CYTK) and Amgen Inc. (Nasdaq: AMGN) today announced that Amgen has exercised its option to obtain an exclusive license, worldwide (excluding Japan), to Cytokinetics’ cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure. Press Releases 2009-05-26T09:14:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_highlights_data_to_be_presented_at_asco1/ http://www.amgennews.com/index.php/2008NewsService/amgen_highlights_data_to_be_presented_at_asco1/#When:09:34:01Z New Vectibix(R) (Panitumumab) Combination Chemotherapy Data New Data Reinforce Importance of Infection Prevention in Chemotherapy Patients Oncology Pipeline Continues to Advance With New Data in Multiple Tumor Types THOUSAND OAKS, Calif. – May 15 – Amgen (Nasdaq: AMGN) today announced it will present new data from the Company’s oncology portfolio of approved and investigational cancer products at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. fromMay 29 to June 2, 2009. Data will be presented from several programs, including Vectibix(R) (panitumumab), Neulasta(R) (pegfilgrastim), Aranesp(R) (darbepoetin alfa), denosumab, conatumumab (AMG 655), dulanermin (rhApo2L/TRAIL) and AMG 479. Press Releases, Product News, Pipeline News 2009-05-15T09:34:01+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_present_at_the_deutsche_bank_34th_annual_healthcare_conference/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_present_at_the_deutsche_bank_34th_annual_healthcare_conference/#When:17:28:00Z THOUSAND OAKS, Calif. – May 13 – Amgen (Nasdaq: AMGN) will present at theDeutsche Bank 34th Annual Healthcare Conference on Monday, May 18, 2009 at the InterContinental,Boston, Mass., beginning at 9:20 a.m. Eastern Time. Chairman and Chief Executive Officer  Kevin Sharer will present. Live audio of the presentation will be available over the Internet and can be accessed fromAmgen’s Web site, www.amgen.com, under Investors. Press Releases 2009-05-13T17:28:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_and_onsedge_partner_with_cancer_survivor_jan_ping_for_new_campaign/ http://www.amgennews.com/index.php/2008NewsService/amgen_and_onsedge_partner_with_cancer_survivor_jan_ping_for_new_campaign/#When:17:25:00Z THOUSAND OAKS, Calif. – April 30 – Amgen and ONSEdge, a subsidiary of the Oncology Nursing Society (ONS), today announced that they will partner alongside celebrity make-up artist and cancer survivor Jan Ping to support a new educational campaign, Coping with Cancer From the Outside In. The initiative is aimed at educating oncology nurses about the skin-related side effects associated with epidermal growth factor receptor (EGFR) inhibitors that are used to treat metastatic colorectal, lung, pancreatic, and head and neck cancers. Press Releases 2009-04-30T17:25:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_and_wyeth_announce_enbrel_support_program/ http://www.amgennews.com/index.php/2008NewsService/amgen_and_wyeth_announce_enbrel_support_program/#When:10:35:00Z Amgen and Wyeth remain committed to helping to provide clinically appropriate patients access to Enbrel® (etanercept), despite tough economic times. Once physicians and their patients have determined that ENBREL is the right treatment choice, patients may benefit from the ENBREL Support™ program, which offers financial support to eligible patients in several ways, depending on their specific situation. Product News 2009-04-24T10:35:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgens_first_quarter_2009_adjusted_earnings_per_share_decreased_4_percent_t/ http://www.amgennews.com/index.php/2008NewsService/amgens_first_quarter_2009_adjusted_earnings_per_share_decreased_4_percent_t/#When:15:15:00Z First Quarter 2009 Revenue Decreased 8 Percent to $3.3 Billion  First Quarter 2009 GAAP Earnings Per Share Decreased 3 Percent to $0.98 2009 Total Revenue Guidance Range Lowered from $14.8 to $15.2 Billion to $14.4 to $14.8 Billion 2009 Adjusted Earnings Per Share Guidance Range Maintained at $4.55 to $4.75   THOUSAND OAKS, Calif. – April 23 /– Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.08 for the first quarter of 2009, a decrease of 4 percent compared to $1.12for the first quarter of 2008. Adjusted net income decreased 8 percent to $1,120 million in the first quarter of 2009 compared to $1,218 million in the first quarter of 2008. Press Releases 2009-04-23T15:15:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2009_first_quarter_financial_results/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2009_first_quarter_financial_results/#When:14:12:00Z THOUSAND OAKS, Calif. – April 20 – Amgen (Nasdaq: AMGN) today announced that it plans to report its first quarter financial results on Thursday, April 23, 2009 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. Press Releases 2009-04-20T14:12:00+00:00